Research Analysts’ Recent Ratings Updates for Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics (NASDAQ: ARQT) recently received a number of ratings updates from brokerages and research firms:

• 8/20/2026 – Arcutis Biotherapeutics was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 8/8/2026 – Arcutis Biotherapeutics was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 8/6/2026 – Arcutis Biotherapeutics was upgraded by Weiss Ratings from “sell (d-)” to “hold (c-)”.
• 8/6/2026 – Arcutis Biotherapeutics had its price target raised by Morgan Stanley from $34.00 to $38.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Arcutis Biotherapeutics had its price target raised by Guggenheim from $35.00 to $38.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Arcutis Biotherapeutics had its price target raised by Needham & Company LLC from $36.00 to $40.00. They now have a “buy” rating on the stock.
• 7/12/2026 – Arcutis Biotherapeutics was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 4,375 shares of Arcutis Biotherapeutics stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the sale, the insider owned 717,203 shares of the company’s stock, valued at approximately $18,733,342.36. The trade was a 0.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sue-Jean Lin sold 4,946 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.38, for a total value of $120,583.48. Following the sale, the director owned 27,567 shares in the company, valued at approximately $672,083.46. The trade was a 15.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 35,967 shares of company stock worth $926,898 over the last 90 days. Insiders own 9.40% of the company’s stock.

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.